8-氯-5,10-二氢-11H-二苯并[b,e][1,4]二氮杂卓-11-酮 | 50892-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 中文名称: 8-氯-5,10-二氢-11H-二苯并[b,e][1,4]二氮杂卓-11-酮
• 中文别名: 氯氮平杂质A；氯氮平(环合物)；8-氯-5,1-二氢-11H-二苯并[b,e][1,4]二氮杂卓-11-酮
• 英文名称: 8-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
• 英文别名: 8-chloro-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one；8-chloro-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one；A-45444；3-chloro-5,11-dihydrobenzo[b][1,4]benzodiazepin-6-one
• CAS: 50892-62-1
• 化学式: C₁₃H₉ClN₂O
• mdl: MFCD01863368
• 分子量: 244.68
• InChiKey: YVWNDABPZGGQFE-UHFFFAOYSA-N

物化性质

• 熔点：
  233-236°C
• 沸点：
  334.4±41.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微超声处理）、甲醇（轻微超声处理）
• 稳定性/保质期：

  将食品放入冷冻室保存。

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  -20°C 冰箱

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 8-Chloro-5,10-dihydro-11h-dibenzo[b,e][1,4]-diazepin-11-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 8-Chloro-5,10-dihydro-11h-dibenzo[b,e][1,4]-diazepin-11-one
CAS number: 50892-62-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H9ClN2O
Molecular weight: 244.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：氯氮平的中间体。

反应信息

• 作为反应物：
  描述：

  8-氯-5,10-二氢-11H-二苯并[b,e][1,4]二氮杂卓-11-酮 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 8-氯-11-(1-哌嗪基)-5H-二苯并[B,E] [1,4]吡喃
  参考文献：
  名称：

  The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs

  摘要：

  Over the past decade, two independent technologies have emerged and been widely adopted by the neuroscience community for remotely controlling neuronal activity: optogenetics which utilize engineered channelrhodopsin and other opsins, and chemogenetics which utilize engineered G protein-coupled receptors (Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)) and other orthologous ligand receptor pairs. Using directed molecular evolution, two types of DREADDs derived from human muscarinic acetylcholine receptors have been developed: hM3Dq which activates neuronal firing, and hM4Di which inhibits neuronal firing. Importantly, these DREADDs were not activated by the native ligand acetylcholine (ACh), but selectively activated by dozapine N-oxide (CNO), a pharmacologically inert ligand. CNO has been used extensively in rodent models to activate DREADDs, and although CNO is not subject to significant metabolic transformation in mice, a small fraction of CNO is apparently metabolized to clozapine in humans and guinea pigs, lessening the translational potential of DREADDs. To effectively translate the DREADD technology, the next generation of DREADD agonists are needed and a thorough understanding of structure activity relationships (SARs) of DREADDs is required for developing such ligands. We therefore conducted the first SAR studies of hM3Dq. We explored multiple regions of the scaffold represented by CNO, identified interesting SAR trends, and discovered several compounds that are very potent hM3Dq agonists but do not activate the native human M3 receptor (hM3). We also discovered that the approved drug perlapine is a novel hM3Dq agonist with >10 000-fold selectivity for hM3Dq over hM3.

  DOI：

  10.1021/cn500325v
• 作为产物：
  描述：

  2,5-二氯硝基苯 在 iron(III) chloride hexahydrate 、 一水合肼 、 copper(l) chloride 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 28.0h， 生成 8-氯-5,10-二氢-11H-二苯并[b,e][1,4]二氮杂卓-11-酮
  参考文献：
  名称：

  一种氯氮平中间体的制备方法

  摘要：

  本发明公开了一种氯氮平中间体的制备方法，属于化合物制备技术领域，该制备方法包括还原反应，缩合反应，环合反应；所述还原反应，将2,5‑二氯硝基苯，催化剂六水合三氯化铁，溶剂无水乙醇混合后，搅拌升温回流，滴加水合肼溶液，滴完后继续升温回流，过滤；所述缩合反应，将2,5‑二氯苯胺与无水乙醇混合后，室温条件下滴加Boc酸酐，滴完后升温反应后降温；所述环合反应，将2,5‑二氯‑Boc‑苯胺，苯胺，催化剂氯化亚铜，有机溶剂混合后，升温反应后降温，抽滤；本发明的制备方法利用Boc保护基结构特点通过一步反应实现乌尔曼缩合与傅克酰基化，缩短了合成路线，还能够降低成本，提高收率和纯度，改善产品质量。

  公开号：

  CN114380755A

文献信息

• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009137499A1

  公开（公告）日：2009-11-12

  Compounds which are histone deacetylase inhibitors and their use in treating various disorders, including Alzheimer's Disease.

  组合物是组蛋白去乙酰化酶抑制剂，用于治疗各种疾病，包括阿尔茨海默病。
• [EN] NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RECEPTEUR DE PROGESTERONE NON STEROIDES
  申请人：AKZO NOBEL NV

  公开号：WO2003084963A1

  公开（公告）日：2003-10-16

  The present invention provides compounds according to general Formula (I), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a prodrug thereof. More particularly, the present invention provides high affinity non-steroidal compounds which are agonists, partial agonists or antagonists of the progesterone receptor.

  本发明提供了符合一般式（I）的化合物，其前药，其药学上可接受的盐，或其前药的药学上可接受的盐。更具体地，本发明提供了高亲和力的非类固醇化合物，它们是孕激素受体的激动剂、部分激动剂或拮抗剂。
• Synthesis and Preliminary Pharmacological Evaluation of 4´-Arylmethyl Analogues of Clozapine. I. The Effect of Aromatic Substituents
  作者：B. Capuano、I. T. Crosby、E. J. Lloyd、D. A. Taylor

  DOI：10.1071/ch02093

  日期：——

  dopamine D4 and serotonin 5-HT2A antagonist activity with potential for the treatment of schizophrenia, we report a family of compounds based on structural modification of the atypical antipsychotic, clozapine (2). The chemical synthesis, structural characterization and pharmacological evaluation of a series 4�-arylmethyl analogues of clozapine are described. Preliminary receptor binding data are presented

  作为开发具有混合多巴胺 D4 和 5-HT2A 拮抗剂活性且具有治疗精神分裂症潜力的化合物的研究计划的一部分，我们报告了基于非典型抗精神病药物氯氮平 (2) 的结构修饰的化合物家族。描述了一系列 4’-芳甲基氯氮平类似物的化学合成、结构表征和药理学评价。提供了初步的受体结合数据，主要检查取代基对引入的芳甲基的电子和位置影响，其次是芳环的性质。
• DIBENZO[b,e][1,4]DIAZEPINE MODULATORS OF DOPAMINE RECEPTORS, SEROTONIN RECEPTORS, ADRENERGIC RECEPTORS, ACETYLCHOLINE RECEPTORS, AND/OR HISTAMINE RECEPTORS
  申请人：Gant Thomas G.

  公开号：US20100166887A1

  公开（公告）日：2010-07-01

  The present invention relates to new dibenzo[b,e][1,4]diazepine modulators of dopamine receptors, serotonin receptors, adrenergic receptors, acetylcholine receptors, and/or histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及新的二苯并[b,e][1,4]二氮杂蒽类多巴胺受体、5-羟色胺受体、肾上腺素受体、乙酰胆碱受体和/或组胺受体调节剂，其药物组成物，以及其使用方法。